Novo Nordisk’s Double Win: FDA Curbs Copycats as Ozempic Pill Replaces Rybelsus

Novo Nordisk gains nearly 5% as FDA targets copycat weight-loss drugs and rebrands Rybelsus as the 'Ozempic pill' to boost US sales.

The stars are aligning for Novo Nordisk in the United States. The Danish drugmaker is simultaneously rolling out a rebranded version of its oral diabetes treatment and benefiting from a regulatory crackdown on cheap knock-offs of its blockbuster weight-loss injections. The twin developments sent its US-listed shares surging nearly 5% on Thursday to $42.22, a move echoed by a similar gain on Friday that pushed the stock to $42.20.

At the heart of the regulatory shift is a plan by the US Food and Drug Administration to remove active ingredients such as semaglutide from a list that permits large-scale compounding by pharmacies. With official shortages of the drug now resolved, the legal justification for these copycat versions evaporates. If the proposal survives a public comment period ending June 29, 2026, telemedicine providers and compounding pharmacies that have been churning out cheaper alternatives will face a severe blow. For Novo Nordisk, the move locks in its market share against unauthorized competition.

A Branding Overhaul with a Familiar Name

Parallel to the FDA’s action, Novo Nordisk is overhauling its US oral portfolio. From May 4, the diabetes drug Rybelsus will vanish from American pharmacy shelves, replaced by what the company is calling the “Ozempic pill.” The tablet contains the same active ingredient, semaglutide, but features a modified coating and a smaller size designed to improve bioavailability. The rebranding taps into the immense recognition of the Ozempic name, which has become synonymous with weight loss globally. Rybelsus had struggled to meet sales expectations, and the company hopes the new label will drive patient uptake.

The pricing strategy is tiered. Insured patients will pay around $25 for a three-month prescription. For those paying out of pocket, monthly costs start at $149 for the introductory dose and climb to $299 through the GoodRx network. Weight Watchers has also signed on to integrate the pill into its medical weight-loss program for diabetics. The name change is limited to the US; Rybelsus will remain on sale in the rest of the world.

Competing in the Oral GLP-1 Race

Novo Nordisk currently dominates the oral GLP-1 market. Recent US prescription data shows more than 85,000 new weekly scripts for its Wegovy tablet, dwarfing the roughly 1,200 scripts for Eli Lilly’s new entrant, Foundayo. Lilly, however, is not standing still. The US rival raised its full-year revenue guidance to as much as $85 billion, signaling aggressive ambitions.

The competitive landscape is intensifying, but Novo Nordisk’s valuation remains relatively modest. The stock trades at a price-to-earnings ratio of around 11.7, well below its mid-2024 peak. Some analysts are cautious. Investment banks including Citi and Bernstein have downgraded the stock ahead of the company’s first-quarter results, due May 6. They expect a roughly 16% year-on-year decline in earnings, squeezed by pricing pressure and thinning margins.

What Investors Are Watching

The Q1 report will offer the first hard data on the Ozempic pill’s market reception. Investors will also be looking for updates on the pipeline, particularly a high-dose 25-milligram version of the new pill, which faces an FDA decision by year-end. The key question is how quickly the new FDA rules will translate into a tangible boost in Novo Nordisk’s US market share.

For now, the combination of a regulatory tailwind and a bold branding move has given the stock a much-needed lift. But with earnings expected to show a dip, the real test lies in whether the company can convert this momentum into sustained growth.